Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.51 |
| ▸ | BRD4 | O60885 | 14/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6791840 | 0.93 | DYRK1A (0.51) | DYRK1ABRD4PTGS2DRD2KDM4E | |
| SCHEMBL6793931 | 0.87 | DYRK1A (0.50) | DYRK1ABRD4DRD2KDM4ENPC1 | |
| SCHEMBL6791887 | 0.77 | SUV39H2 (0.42) | DYRK1ABRD4DRD2 | |
| SCHEMBL31357648 | 0.74 | BCHE (0.46) | BRD4DRD2NPC1RAB9A | |
| SCHEMBL6786895 | 0.73 | DYRK1A (0.43) | DYRK1ABRD4DRD2KDM4ENPC1 | |
| SCHEMBL6794270 | 0.72 | DYRK1A (0.42) | DYRK1ABRD4DRD2KDM4ENPC1 | |
| SCHEMBL4712902 | 0.72 | GABRP (0.47) | DYRK1ABRD4DRD2NPC1RAB9A | |
| SCHEMBL26696082 | 0.71 | BRD4 (0.47) | DYRK1ABRD4PTGS2DRD2KDM4E | |
| SCHEMBL6793960 | 0.70 | BRD4 (0.38) | DYRK1ABRD4DRD2NPC1RAB9A | |
| SCHEMBL4712740 | 0.70 | DYRK1A (0.45) | DYRK1ABRD4DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | DYRK1A 754/4885BRD4 833/4885PTGS2 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.